JWH 201

Confirm delete?

JWH 201

Zoom

Cat No: 10721

Biochemicals - Drugs Of Abuse

JWH 201 is a synthetic cannabinoid (CB) with relatively poor affinities for both CB1 (Ki = 1.1 μM) and CB2 (Ki = 0.44 μM) receptors.{17655} It is a para-methoxy analog of the more potent cannabimimetic JWH 250 (Item No. 13634).

This article is not for sale online.
Contact us for more information about this article.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

                                            Technical Warning: Bertin Technologies restricts the sale of this product to licensed controlled substance laboratories and qualified academic research institutions. Please contact us for further details.
                    

                        Special Advice: Please check regulation status before ordering; additionel fees can apply. 
                    

Synonyms:

2-(4-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone

Correlated keywords:

cannabinoids CB1 CB2 receptors CBs JWH201 JWH-201 JWH250 JWH-250 JWH 250 analytical references standards

Product Overview:
JWH 201 is a synthetic cannabinoid (CB) with relatively poor affinities for both CB1 (Ki = 1.1 μM) and CB2 (Ki = 0.44 μM) receptors.{17655} It is a para-methoxy analog of the more potent cannabimimetic JWH 250 (Item No. 13634).

Size	10 mg
Shipping	dry ice
CAS Number	864445-47-6
Molecular Formula	C₂₂H₂₅NO₂
SMILES	O=C(CC1=CC=C(OC)C=C1)C2=CN(CCCCC)C3=CC=CC=C32
Molecular Weight	335,4
Formulation	A solution in methyl acetate
Purity	≥98%
Custom Code	2933.49
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.